| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Stroke Unit, Department of Neurology (Dr. Tanne), Chaim Sheba Medical Center, Tel Hashomer, Israel; Department of Clinical Neurosciences (Drs. Demchuk and Hill), Foothills Hospital, Calgary, Canada; Comprehensive Stroke Center (Dr. Kasner), University of Pennsylvania Medical Center, Philadelphia, PA; Park Nicollet Neuroscience (Dr. Hanson), St. Louis Park, MN; Klinik für Neurologie der Universität zu Köln (Dr. Grond), Köln, Germany; Henry Ford Hospital and Health Science Center (Dr. Levine), Detroit, MI.
Address correspondence and reprint requests to Dr. Michael D. Hill, MRG005, Foothills Hospital, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada; email: michael.hill{at}crha-health.ab.ca
Background:— Thrombolytic therapy for acute ischemic stroke with IV alteplase is increasingly well established in North America but not elsewhere. Baseline factors that altered the response to alteplase were not identified by the National Institute of Neurological Disorders and Stroke tPA Stroke Study Group.
Methods:— The authors gathered information from centers in the United States, Canada, and Germany on 1,205 patients with acute ischemic stroke treated with IV alteplase. The purpose was to identify independent factors that were predictive of good outcome using multivariable logistic regression modelling. The modified Rankin Scale score was dichotomized into good outcome (mRS 0 to 1) and poor outcome (mRS >1) as the primary outcome measure.
Results:— In relative order of decreasing magnitude, milder baseline stroke severity, no history of diabetes mellitus, normal CT scan, normal pretreatment blood glucose level, and normal pretreatment blood pressure were independent predictors of good outcome among patients treated with IV alteplase for acute ischemic stroke. Confounding was observed among history of diabetes mellitus, CT scan appearance, baseline serum glucose level, and blood pressure, suggesting important relationships among these variables.
Conclusions:— Several factors were independently predictive of good outcome among patients with acute ischemic stroke treated with alteplase. These results require further confirmation before clinical implementation.
This article has been cited by other articles:
|
|
 |
|
  E. Meseguer, M. Mazighi, J. Labreuche, C. Arnaiz, L. Cabrejo, T. Slaoui, C. Guidoux, J.-M. Olivot, H. Abboud, B. Lapergue, et al. Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender: A Clinical Registry Study and Systematic Review Stroke, June 1, 2009; 40(6): 2104 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shuaib Disappearance of the hyperdense MCA sign after thrombolysis: is it a predictor of better prognosis in patients with acute ischaemic stroke? J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 248 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Martin-Schild, H. Hallevi, K. C. Albright, A. M. Khaja, A. D. Barreto, N. R. Gonzales, J. C. Grotta, and S. I. Savitz Aggressive Blood Pressure-Lowering Treatment Before Intravenous Tissue Plasminogen Activator Therapy in Acute Ischemic Stroke Arch Neurol, September 1, 2008; 65(9): 1174 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.S.V. Elkind, S. Prabhakaran, J. Pittman, W. Koroshetz, M. Jacoby, K. C. Johnston, and for the GAIN Americas Investigators Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke Neurology, March 13, 2007; 68(11): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tsivgoulis, M. Saqqur, V. K. Sharma, A. Y. Lao, M. D. Hill, A. V. Alexandrov, and for the CLOTBUST Investigators Association of Pretreatment Blood Pressure With Tissue Plasminogen Activator-Induced Arterial Recanalization in Acute Ischemic Stroke Stroke, March 1, 2007; 38(3): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saqqur, K. Uchino, A. M. Demchuk, C. A. Molina, Z. Garami, S. Calleja, N. Akhtar, F. O. Orouk, A. Salam, A. Shuaib, et al. Site of Arterial Occlusion Identified by Transcranial Doppler Predicts the Response to Intravenous Thrombolysis for Stroke Stroke, March 1, 2007; 38(3): 948 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Banks and C. A. Marotta Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials: A Literature Review and Synthesis Stroke, March 1, 2007; 38(3): 1091 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Engelter, L. H. Bonati, and P. A. Lyrer Intravenous thrombolysis in stroke patients of >=80 versus <80 years of age--a systematic review across cohort studies. Age Ageing, November 1, 2006; 35(6): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. U. Weir, J. H. W. Pexman, M. D. Hill, A. M. Buchan, and on behalf of the CASES investigators How well does ASPECTS predict the outcome of acute stroke treated with IV tPA? Neurology, August 8, 2006; 67(3): 516 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Engelter, M. Reichhart, L. Sekoranja, D. Georgiadis, A. Baumann, B. Weder, F. Muller, R. Luthy, M. Arnold, P. Michel, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis Neurology, December 13, 2005; 65(11): 1795 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marti-Fabregas, M. Borrell, D. Cocho, R. Belvis, M. Castellanos, J. Montaner, J. Pagonabarraga, A. Aleu, L. Molina-Porcel, J. Diaz-Manera, et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA Neurology, August 9, 2005; 65(3): 366 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saposnik, B. Young, B. Silver, S. Di Legge, F. Webster, V. Beletsky, V. Jain, Y. Nilanont, and V. Hachinski Lack of Improvement in Patients With Acute Stroke After Treatment With Thrombolytic Therapy: Predictors and Association With Outcome JAMA, October 20, 2004; 292(15): 1839 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ribo, J. Montaner, C. A. Molina, J. F. Arenillas, E. Santamarina, M. Quintana, and J. Alvarez-Sabin Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator Stroke, September 1, 2004; 35(9): 2123 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Felberg Editorial Comment--The MOST Score: Modifying the Open-Artery "Good"-Closed-Artery "Bad" Approach to Thrombolysis Prognosis Stroke, January 1, 2004; 35(1): 156 - 157. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Molina, A. V. Alexandrov, A. M. Demchuk, M. Saqqur, K. Uchino, and J. Alvarez-Sabin Improving the Predictive Accuracy of Recanalization on Stroke Outcome in Patients Treated With Tissue Plasminogen Activator Stroke, January 1, 2004; 35(1): 151 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. U. Heuschmann, K. Berger, B. Misselwitz, P. Hermanek, C. Leffmann, M. Adelmann, H.-J. Buecker-Nott, J. Rother, B. Neundoerfer, and P. L. Kolominsky-Rabas Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk of In-Hospital Mortality: The German Stroke Registers Study Group Stroke, May 1, 2003; 34(5): 1106 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tanne and Y. Schwammenthal Editorial Comment--Hyperglycemia and Early Reperfusion Therapy Stroke, May 1, 2003; 34(5): 1240 - 1241. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, S. R. Levine, M. R. Frankel, T. G. Brott, Y. Lin, B. C. Tilley, P. D. Lyden, J. P. Broderick, T. G. Kwiatkowski, and S. E. Fineberg Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial Neurology, September 10, 2002; 59(5): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.A. Ringleb, P.D. Schellinger, C. Schranz, and W. Hacke Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke: Useful or Harmful? Stroke, May 1, 2002; 33(5): 1437 - 1441. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
